$84.63
At close: Apr 16 EDT
$84.50
-0.13-0.15%
Pre-Market: 4:15 AM EDT
Comments
Loading...
LeMaitre Vascular Analyst Ratings and Price Targets | NASDAQ:LMAT | Benzinga
LeMaitre Vascular Inc has a consensus price target of $94 based on the ratings of 11 analysts. The high is $110 issued by Lake Street on February 28, 2025. The low is $67 issued by Jefferies on August 3, 2023. The 3 most-recent analyst ratings were released by Lake Street, Citizens Capital Markets, and Wells Fargo on February 28, 2025, February 28, 2025, and February 13, 2025, respectively. With an average price target of $105 between Lake Street, Citizens Capital Markets, and Wells Fargo, there's an implied 24.26% upside for LeMaitre Vascular Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Lake Street
Citizens Capital Markets
Wells Fargo
Oppenheimer
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for LeMaitre Vascular
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/28/2025 | Buy Now | 30.18% | Lake Street | Brooks O'Neil34% | $105 → $110 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 30.18% | Citizens Capital Markets | Daniel Stauder32% | $105 → $110 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | — | Barrington Research | Michael Petusky48% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 02/13/2025 | Buy Now | 12.43% | Wells Fargo | Nathan Treybeck55% | → $95 | Initiates | → Equal-Weight | Get Alert |
| 11/01/2024 | Buy Now | 10.06% | Oppenheimer | Suraj Kalia54% | $90 → $93 | Reiterates | Outperform → Outperform | Get Alert |
| 11/01/2024 | Buy Now | 10.06% | Barrington Research | Michael Petusky48% | $92 → $93 | Maintains | Outperform | Get Alert |
| 10/15/2024 | Buy Now | 13.61% | Cantor Fitzgerald | Ross Osborn42% | → $96 | Initiates | → Neutral | Get Alert |
| 09/20/2024 | Buy Now | 8.88% | Barrington Research | Michael Petusky48% | $92 → $92 | Maintains | Outperform | Get Alert |
| 08/20/2024 | Buy Now | 18.34% | JMP Securities | Daniel Stauder32% | $77 → $100 | Maintains | Market Outperform | Get Alert |
| 08/02/2024 | Buy Now | 8.88% | Barrington Research | Michael Petusky48% | $79 → $82 | Maintains | Outperform | Get Alert |
| 05/31/2024 | Buy Now | 18.34% | Roth MKM | Jason Wittes51% | → $100 | Reinstates | → Buy | Get Alert |
| 05/03/2024 | Buy Now | -6.51% | Barrington Research | Michael Petusky48% | $69 → $79 | Maintains | Outperform | Get Alert |
| 05/03/2024 | Buy Now | -8.88% | JMP Securities | Daniel Stauder32% | $72 → $77 | Maintains | Market Outperform | Get Alert |
| 04/26/2024 | Buy Now | -11.24% | Stifel | Rick Wise73% | $59 → $75 | Upgrade | Hold → Buy | Get Alert |
| 02/28/2024 | Buy Now | -18.34% | Barrington Research | Michael Petusky48% | $66 → $69 | Maintains | Outperform | Get Alert |
| 02/06/2024 | Buy Now | — | Keybanc | Brett Fishbin48% | — | Initiates | → Sector Weight | Get Alert |
| 10/23/2023 | Buy Now | -28.99% | JMP Securities | Daniel Stauder32% | → $60 | Initiates | → Market Outperform | Get Alert |
| 09/06/2023 | Buy Now | -17.16% | Oppenheimer | Suraj Kalia54% | → $70 | Initiates | → Outperform | Get Alert |
| 08/03/2023 | Buy Now | -20.71% | Jefferies | Anthony Petrone64% | $63 → $67 | Downgrade | Buy → Hold | Get Alert |
| 08/02/2023 | Buy Now | -11.24% | Lake Street | Brooks O'Neil34% | $65 → $75 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | -21.89% | Barrington Research | Michael Petusky48% | $62 → $66 | Maintains | Outperform | Get Alert |
| 05/03/2023 | Buy Now | -26.63% | Barrington Research | Michael Petusky48% | → $62 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/28/2022 | Buy Now | — | Barrington Research | Michael Petusky48% | — | Downgrade | Outperform → Market Perform | Get Alert |
FAQ
What is the target price for LeMaitre Vascular (LMAT) stock?
The latest price target for LeMaitre Vascular (NASDAQ:LMAT) was reported by Lake Street on February 28, 2025. The analyst firm set a price target for $110.00 expecting LMAT to rise to within 12 months (a possible 30.18% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for LeMaitre Vascular (LMAT)?
The latest analyst rating for LeMaitre Vascular (NASDAQ:LMAT) was provided by Lake Street, and LeMaitre Vascular maintained their buy rating.
When was the last upgrade for LeMaitre Vascular (LMAT)?
The last upgrade for LeMaitre Vascular Inc happened on April 26, 2024 when Stifel raised their price target to $75. Stifel previously had a hold for LeMaitre Vascular Inc.
When was the last downgrade for LeMaitre Vascular (LMAT)?
The last downgrade for LeMaitre Vascular Inc happened on February 28, 2025 when Barrington Research changed their price target from N/A to N/A for LeMaitre Vascular Inc.
When is the next analyst rating going to be posted or updated for LeMaitre Vascular (LMAT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LeMaitre Vascular, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LeMaitre Vascular was filed on February 28, 2025 so you should expect the next rating to be made available sometime around February 28, 2026.
Is the Analyst Rating LeMaitre Vascular (LMAT) correct?
While ratings are subjective and will change, the latest LeMaitre Vascular (LMAT) rating was a maintained with a price target of $105.00 to $110.00. The current price LeMaitre Vascular (LMAT) is trading at is $84.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.